(NUS) Nu Skin Enterprises - Overview

Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 352m USD | Total Return: -16% in 12m

Skin Care, Nutritional Supplements, Beauty Devices, Cosmetics
Total Rating 32
Safety 87
Buy Signal -0.58
Household & Personal Products
Industry Rotation: +5.0
Market Cap: 352M
Avg Turnover: 3.71M
Risk 3d forecast
Volatility52.8%
VaR 5th Pctl8.37%
VaR vs Median-4.26%
Reward TTM
Sharpe Ratio-0.12
Rel. Str. IBD4.5
Rel. Str. Peer Group25
Character TTM
Beta1.394
Beta Downside1.305
Hurst Exponent0.461
Drawdowns 3y
Max DD83.58%
CAGR/Max DD-0.51
CAGR/Mean DD-0.68
EPS (Earnings per Share) EPS (Earnings per Share) of NUS over the last years for every Quarter: "2021-03": 0.91, "2021-06": 1.15, "2021-09": 0.97, "2021-12": 1.11, "2022-03": 0.76, "2022-06": 0.77, "2022-09": 0.47, "2022-12": 0.89, "2023-03": 0.37, "2023-06": 0.54, "2023-09": 0.56, "2023-12": 0.37, "2024-03": 0.09, "2024-06": 0.21, "2024-09": 0.17, "2024-12": 0.38, "2025-03": 2.1363, "2025-06": 0.43, "2025-09": 0.34, "2025-12": 0.29, "2026-03": 0.14,
EPS CAGR: -36.53%
EPS Trend: -32.1%
Last SUE: -0.19
Qual. Beats: 0
Revenue Revenue of NUS over the last years for every Quarter: 2021-03: 677.026, 2021-06: 704.055, 2021-09: 641.152, 2021-12: 673.436, 2022-03: 604.899, 2022-06: 560.615, 2022-09: 537.805, 2022-12: 522.34, 2023-03: 481.462, 2023-06: 500.257, 2023-09: 498.772, 2023-12: 488.64, 2024-03: 417.306, 2024-06: 439.081, 2024-09: 430.145, 2024-12: 445.552, 2025-03: 364.49, 2025-06: 386.138, 2025-09: 364.211, 2025-12: 370.32, 2026-03: 320.608,
Rev. CAGR: -13.84%
Rev. Trend: -95.3%
Last SUE: -1.04
Qual. Beats: -2

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: NUS Nu Skin Enterprises

Nu Skin Enterprises, Inc. (NUS) is a global beauty and wellness company specializing in anti-aging skincare, nutritional supplements, and personal care devices. The firm operates through a multi-channel distribution strategy, utilizing direct-to-consumer digital platforms, retail locations, and a network of independent sales representatives across major markets in Asia, the Americas, and Europe.

The company operates within the personal care products sector, a market characterized by high consumer loyalty and recurring revenue streams from consumable goods. Nu Skin’s business model integrates proprietary hardware, such as data-enabled wellness devices, with specialized topical treatments to create a closed-loop product ecosystem.

For more detailed financial metrics and valuation trends, consider reviewing the comprehensive data available on ValueRay.

Headquartered in Provo, Utah, the company manages a diverse brand portfolio including ageLOC, Pharmanex, and Nutricentials. Its research and development efforts focus on the intersection of biotechnology and skincare to maintain competitive differentiation in the premium wellness segment.

Headlines to Watch Out For
  • Mainland China revenue stability dictates overall corporate growth and investor sentiment
  • Direct selling regulatory shifts in key Asian markets impact distributor retention
  • Consumer adoption of high-margin beauty device systems drives product mix profitability
  • Global macroeconomic volatility and currency fluctuations pressure international sales margins
  • Expansion of digital commerce platforms determines acquisition costs for younger demographics
Piotroski VR‑10 (Strict) 5.0
Net Income: 54.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.72 > 1.0
NWC/Revenue: 18.45% < 20% (prev 15.75%; Δ 2.69% < -1%)
CFO/TA 0.06 > 3% & CFO 76.0m > Net Income 54.5m
Net Debt (79.0m) to EBITDA (115.4m): 0.68 < 3
Current Ratio: 2.03 > 1.5 & < 3
Outstanding Shares: last quarter (49.4m) vs 12m ago -1.80% < -2%
Gross Margin: 69.31% > 18% (prev 0.68%; Δ 6.86k% > 0.5%)
Asset Turnover: 104.1% > 50% (prev 120.7%; Δ -16.56% > 0%)
Interest Coverage Ratio: 4.92 > 6 (EBITDA TTM 115.4m / Interest Expense TTM 14.9m)
Altman Z'' 9.16
A: 0.19 (Total Current Assets 522.9m - Total Current Liabilities 257.0m) / Total Assets 1.38b
B: 1.35 (Retained Earnings 1.86b / Total Assets 1.38b)
C: 0.05 (EBIT TTM 73.3m / Avg Total Assets 1.38b)
D: 2.99 (Book Value of Equity 1.74b / Total Liabilities 582.7m)
Altman-Z'' Score: 9.16 = AAA
Beneish M -3.23
DSRI: 0.93 (Receivables 45.0m/56.6m, Revenue 1.44b/1.68b)
GMI: 0.98 (GM 69.31% / 67.57%)
AQI: 1.00 (AQ_t 0.29 / AQ_t-1 0.29)
SGI: 0.86 (Revenue 1.44b / 1.68b)
TATA: -0.02 (NI 54.5m - CFO 76.0m) / TA 1.38b)
Beneish M-Score: -3.23 (Cap -4..+1) = AA
What is the price of NUS shares? As of May 16, 2026, the stock is trading at USD 6.12 with a total of 688,455 shares traded.
Over the past week, the price has changed by -14.53%, over one month by -21.44%, over three months by -28.42% and over the past year by -16.00%.
Is NUS a buy, sell or hold? Nu Skin Enterprises has no consensus analysts rating.
What are the forecasts/targets for the NUS price?
Analysts Target Price 7.5 22.5%
Nu Skin Enterprises (NUS) - Fundamental Data Overview as of 12 May 2026
P/E Trailing = 6.6296
P/E Forward = 7.1582
P/S = 0.2443
P/B = 0.4434
P/EG = 0.7782
Revenue TTM = 1.44b USD
EBIT TTM = 73.3m USD
EBITDA TTM = 115.4m USD
Long Term Debt = 204.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 277.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 79.0m USD (from netDebt column, last quarter)
Enterprise Value = 431.1m USD (352.1m + Debt 277.6m - CCE 198.7m)
Interest Coverage Ratio = 4.92 (Ebit TTM 73.3m / Interest Expense TTM 14.9m)
EV/FCF = 10.37x (Enterprise Value 431.1m / FCF TTM 41.6m)
FCF Yield = 9.64% (FCF TTM 41.6m / Enterprise Value 431.1m)
FCF Margin = 2.88% (FCF TTM 41.6m / Revenue TTM 1.44b)
Net Margin = 3.78% (Net Income TTM 54.5m / Revenue TTM 1.44b)
Gross Margin = 69.31% ((Revenue TTM 1.44b - Cost of Revenue TTM 442.4m) / Revenue TTM)
Gross Margin QoQ = 66.89% (prev 70.74%)
Tobins Q-Ratio = 0.31 (Enterprise Value 431.1m / Total Assets 1.38b)
Interest Expense / Debt = 1.53% (Interest Expense 4.25m / Debt 277.6m)
Taxrate = 29.36% (763k / 2.60m)
NOPAT = 51.8m (EBIT 73.3m * (1 - 29.36%))
Current Ratio = 2.03 (Total Current Assets 522.9m / Total Current Liabilities 257.0m)
Debt / Equity = 0.35 (Debt 277.6m / totalStockholderEquity, last quarter 794.1m)
Debt / EBITDA = 0.68 (Net Debt 79.0m / EBITDA 115.4m)
Debt / FCF = 1.90 (Net Debt 79.0m / FCF TTM 41.6m)
Total Stockholder Equity = 796.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.94% (Net Income 54.5m / Total Assets 1.38b)
RoE = 6.84% (Net Income TTM 54.5m / Total Stockholder Equity 796.7m)
RoCE = 7.33% (EBIT 73.3m / Capital Employed (Equity 796.7m + L.T.Debt 204.2m))
RoIC = 5.02% (NOPAT 51.8m / Invested Capital 1.03b)
WACC = 6.57% (E(352.1m)/V(629.7m) * Re(10.89%) + D(277.6m)/V(629.7m) * Rd(1.53%) * (1-Tc(0.29)))
Discount Rate = 10.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.29%
[DCF] Terminal Value 80.34% ; FCFF base≈51.3m ; Y1≈39.1m ; Y5≈24.0m
[DCF] Fair Price = 11.18 (EV 628.8m - Net Debt 79.0m = Equity 549.9m / Shares 49.2m; r=6.57% [WACC]; 5y FCF grow -28.32% → 3.0% )
EPS Correlation: -32.07 | EPS CAGR: -36.53% | SUE: -0.19 | # QB: 0
Revenue Correlation: -95.28 | Revenue CAGR: -13.84% | SUE: -1.04 | # QB: -2
EPS current Quarter (2026-06-30): EPS=0.20 | Chg30d=-13.04% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=+10.34% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=1.00 | Chg30d=+0.00% | Revisions=-20% | GrowthEPS=-21.3% | GrowthRev=-4.0%
EPS next Year (2027-12-31): EPS=1.32 | Chg30d=+0.76% | Revisions=N/A | GrowthEPS=+32.0% | GrowthRev=+7.3%